Abeona Therapeutics, Inc., was incorporated in Wyoming in 1974. The company is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. On April 28, 2025, the U.S. Food and Drug Administration approved ZEVASKYN (prademagene zamikeracel) genetically modified cell sheet as the first and only autologous cell-based gene therapy for the treatment of wounds in adults and children with RDEB, a severe and debilitating hereditary skin disease. RDEB cannot be cured, and ZEVASKYN is the only U.S. Food and Drug Administration-approved product that can treat RDEB wounds in one go. ZEVASKYN has been awarded the orphan drug and rare pediatric disease designation by the U.S. Food and Drug Administration.